China & China — National Medical Products Administration
22 shared events · Importance 3 · Last updated Aug 20, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Tech
China: China has demonstrated leadership in neurotechnology by approving and deploying the first commercial BCI, aligning with its strategic goal to dominate future industries and potentially boosting its tech sector.
China — National Medical Products Administration: The NMPA granted commercial approval to NEO, enabling the first commercial BCI implant and setting a regulatory precedent that may influence future approvals in China.
Jul 06, 2026 · 10 articles
Regulatory
China: The approval of ORPATHYS (savolitinib) in China addresses a significant unmet medical need for gastric cancer patients in the country, where gastric cancer is a leading cause of cancer death.
China — National Medical Products Administration: The China — National Medical Products Administration granted conditional approval for ORPATHYS (savolitinib) for the treatment of gastric cancer, enabling its commercialization in China.
Jul 02, 2026 · 6 articles
Tech
China: China's China — National Medical Products Administration approved the IND application for ATG-201, facilitating the initiation of Phase I clinical trials within the country.
China — National Medical Products Administration: The China — National Medical Products Administration approved the IND application for ATG-201, enabling Antengene to proceed with Phase I clinical trials in China.
Jun 10, 2026 · 8 articles
Regulatory
China: China is the market where the NDA was submitted, representing a significant commercial opportunity for NCX 470.
China — National Medical Products Administration: The NMPA is the regulatory authority reviewing the NDA. Its approval decision will determine market access for NCX 470 in China.
Aug 10, 2026 · 6 articles
Regulatory
China: China is the target market for Lerociclib, with an estimated 400 million individuals suffering from dyslipidemia and a significant unmet medical need for lipid-lowering treatments.
China — National Medical Products Administration: The China — National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA) for Lerociclib, which is a crucial regulatory step for the drug's potential approval and availability in China.
Jun 26, 2026 · 8 articles
Business
China: China is the country where the China — National Medical Products Administration operates and where Gumokimab has been approved for market, impacting its healthcare sector and patient population.
China — National Medical Products Administration: The China — National Medical Products Administration approved Gumokimab, enabling its commercialization in China and providing a new treatment option for patients with moderate-to-severe plaque psoriasis.
Jun 12, 2026 · 7 articles
Business
China: China, through its China — National Medical Products Administration (NMPA), is the regulatory authority that accepted the IND application for HBM7004, facilitating its potential clinical development within the country.
China — National Medical Products Administration: The China — National Medical Products Administration (NMPA) of China accepted the Investigational New Drug (IND) application for HBM7004, allowing Harbour BioMed to advance its drug towards clinical evaluation in China.
Jun 10, 2026 · 7 articles
Business
China: China is the world's second-largest pharmaceutical market and a fast-growing source of drug innovation. VivoSim's entry into China reflects the country's growing demand for advanced preclinical testing services.
China — National Medical Products Administration: The NMPA's record drug approvals and regulatory reforms create a favorable environment for innovative drug development, indirectly supporting demand for VivoSim's services.
Jul 21, 2026 · 6 articles
Business
China: Domestic market remains a key revenue source with steady growth and regulatory approvals, supporting the company's overall performance.
China — National Medical Products Administration: Regulatory body granting approvals for 11 new products, facilitating domestic portfolio expansion and market competitiveness.
Jul 20, 2026 · 7 articles
Tech
China: China is the country where the pivotal Phase II clinical trial for fanregratinib was conducted across 53 sites and where the New Drug Application was accepted for review by the China — National Medical Products Administration.
China — National Medical Products Administration: The China — National Medical Products Administration accepted the New Drug Application for fanregratinib and granted it priority review, indicating a potential expedited path to market approval in China.
Jun 24, 2026 · 6 articles
Business
China: China is the location for the Phase I ATTRACT study of ATG-201, with NMPA approval facilitating clinical trials.
China — National Medical Products Administration: NMPA approved the IND application for ATG-201 Phase I study in China, enabling clinical development in the country.
Jul 13, 2026 · 7 articles
Business
China: The licensing agreement covers the Greater China region, including the Chinese mainland, China — Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan, indicating the geographical scope of the drug's commercialization.
China — National Medical Products Administration: The China — National Medical Products Administration accepted the new drug application for roconkibart in December 2025, indicating progress in the regulatory approval process for the drug.
Jul 01, 2026 · 8 articles
Tech
China: China is the home country of Puncture Robotic and the regulatory origin of HAIRO's NMPA certification.
China — National Medical Products Administration: NMPA Class III certification is a regulatory milestone for HAIRO in China.
Jul 10, 2026 · 6 articles
Business
China: China is the home market where senaparib is already approved and reimbursed, providing a revenue base and validation for the drug.
China — National Medical Products Administration: The NMPA approved senaparib in China in January 2025, enabling its commercialization there. This approval is foundational to the drug's global development.
Jul 31, 2026 · 8 articles
Tech
China: China is the location where the initial PoC clinical study for IBI363 was conducted and where Innovent Biologics is based. The China NMPA has also granted Breakthrough Therapy Designations for IBI363.
China — National Medical Products Administration: The China — National Medical Products Administration (NMPA) of China has granted three Breakthrough Therapy Designations to IBI363, recognizing its potential for significant clinical advantage over existing therapies.
May 21, 2026 · 9 articles
Tech
China: China is a key market for hepatitis B treatment, with 87 million people chronically infected. The China — National Medical Products Administration of China has granted Breakthrough Therapy Designation for BRII-179 and elebsiran.
China — National Medical Products Administration: The China — National Medical Products Administration's Center for Drug Evaluation granted BRII-179 and elebsiran Breakthrough Therapy Designation, and Brii Biosciences has reached preliminary alignment with them regarding a potential registrational study for ENRICH.
Jul 03, 2026 · 7 articles
Tech
China: China is relevant as the country where golidocitinib received approval from the China — National Medical Products Administration (NMPA).
China — National Medical Products Administration: The China — National Medical Products Administration (NMPA) of China approved golidocitinib in June 2024 for r/r PTCL, indicating regulatory progress for one of Dizal Pharmaceutical's key assets.
May 31, 2026 · 6 articles
Tech
China: Sac-TMT has multiple indications approved and marketed in China, with two included in the National Reimbursement Drug List, benefiting patients in the country.
China — National Medical Products Administration: The agency has granted sac-TMT six Breakthrough Therapy Designations and accepted a new indication application for review, indicating regulatory recognition of the drug's potential.
May 30, 2026 · 14 articles
Business
China: CardioACC, one of the companies Medtronic invested in, is based in Shenzhen, China, and received approval for its ICE system from the China — National Medical Products Administration.
China — National Medical Products Administration: The China — National Medical Products Administration approved CardioACC's ICE system in 2025, indicating regulatory acceptance of the technology.
Jun 03, 2026 · 6 articles
Business
China: Ascentage Pharma operates in China and has approvals from Chinese regulators, but this event does not directly impact the country.
China — National Medical Products Administration: The NMPA approved lisaftoclax in 2025, but this event does not directly involve the NMPA.
Jul 26, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how China and China — National Medical Products Administration interact across events, view sentiment trends, and discover connected entities.
Open Dashboard